


## Colistin sulfate

|                           |  |
|---------------------------|--|
| <b>Cat. No.:</b>          | HY-A0089   |
| <b>CAS No.:</b>           | 1264-72-8  |
| <b>Molecular Formula:</b> | C <sub>52</sub> H <sub>98</sub> N <sub>16</sub> O <sub>13</sub> ·2.5H <sub>2</sub> O <sub>4</sub> S                            |
| <b>Molecular Weight:</b>  | 1400.64  |
| <b>Target:</b>            | Bacterial; Autophagy; Antibiotic   |
| <b>Pathway:</b>           | Anti-infection; Autophagy  |
| <b>Storage:</b>           | 4°C, sealed storage, away from moisture<br>* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |



### SOLVENT & SOLUBILITY

|   |   |   |             |             |              |
|---|---|---|-------------|-------------|--------------|
| <b>In Vitro</b>   | H <sub>2</sub> O : 50 mg/mL (35.70 mM); Need ultrasonic   |   |             |             |              |
|   | <b>Preparing Stock Solutions</b>  | <b>Solvent</b> \ <b>Concentration</b> \ <b>Mass</b> | <b>1 mg</b> | <b>5 mg</b> | <b>10 mg</b> |
|   |   | <b>1 mM</b>   | 0.7140 mL   | 3.5698 mL   | 7.1396 mL    |
|   |   | <b>5 mM</b>   | 0.1428 mL   | 0.7140 mL   | 1.4279 mL    |
|   |   | <b>10 mM</b>  | 0.0714 mL   | 0.3570 mL   | 0.7140 mL    |
| Please refer to the solubility information to select the appropriate solvent. |   |   |             |             |              |
| <b>In Vivo</b>  | 1. Add each solvent one by one: PBS<br>Solubility: 50 mg/mL (35.70 mM); Clear solution; Need ultrasonic |   |             |             |              |

### BIOLOGICAL ACTIVITY

|                    |  |
|--------------------|--|
| <b>Description</b> | Colistin sulfate is a polypeptide antibiotic which inhibits gram-negative bacteria by binding to lipopolysaccharides and phospholipids in the outer cell membrane of gram-negative bacteria.   |
| <b>In Vitro</b>    | Colistins are bactericidal to gram-negative bacteria by a detergent-like mechanism. This mechanism involves interaction with lipopolysaccharides and phospholipids of the outer membrane and electrostatic interference with the outer membrane by competitively displacing divalent cations (calcium and magnesium) from the negatively charged phosphate groups of membrane lipids <sup>[1]</sup> . Colistin (polymyxin E) owns favorable properties of rapid bacterial killing, a narrow spectrum of activity, and an associated slow development of resistance for the treatment of infections caused by multidrug-resistant gram-negative bacteria. There are two forms of colistin available commercially: colistin (sulfate) mainly for topical use and colistin methanesulfonate (sodium) for parenteral use <sup>[2]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| <b>In Vivo</b>     | High concentrations of colistin in rat ELF are achieved as a result of slow and sustained CMS conversion following i.t. instillation <sup>[3]</sup> . Colistin is often used in piglets but underdosing and overdosing are frequent. Under- or overdoses of colistin   |

do not result in any major disturbance of piglet fecal microbiota and rarely select for chromosomal resistance in the dominant *E. coli* population<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Animal Administration <sup>[3]</sup>

Rats: Colistin methanesulfonate (sodium) and colistin (sulfate) dosing solutions are freshly prepared in sterile 0.9% sodium chloride. For the i.v. studies, colistin methanesulfonate (CMS) or sulfate solutions are administered by a bolus injection via the jugular vein cannula. Intratracheal (i.t.) instillation is utilized as the technique for pulmonary administration. Animals are administered i.v. CMS at doses of 14 mg/kg of body weight, 28 mg/kg or 56 mg/kg. In an independent study, rats are administered i.v. colistin at doses of 0.21 mg/kg, 0.41 mg/kg, or 0.62 mg/kg<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Nat Commun. 2022 Mar 2;13(1):1116.
- Adv Sci (Weinh). 2020 Jul 21;7(17):2001374.
- Clin Microbiol Infect. 2020 Sep;26(9):1264-1265.
- Emerg Microbes Infect. 2024 Dec;13(1):2321981.
- Microorganisms. 2024 Mar 13, 12(3), 575.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Hancock RE et al. Peptide antibiotics. *Antimicrob Agents Chemother.* 1999 Jun;43(6):1317-23.

[2]. Li J, et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis. *Antimicrob Agents Chemother.* 2001 Mar;45(3):781-5.

[3]. W S Yapa S, et al. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. *Antimicrob Agents Chemother.* 2013 Oct;57(10):5087-95.

[4]. Fleury MA, et al. Impact of two different colistin dosing strategies on healthy piglet fecal microbiota. *Res Vet Sci.* 2016 Aug;107:152-60.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA